{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:44:23Z","timestamp":1791521063741,"version":"4.3.4"},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma (NHL) confined to the brain, leptomeninges, eyes, or spinal cord. The majority of PCNSL cases occur in the immunocompetent host, the focus of this review. The prognosis of PCNSL is inferior to that of other NHL subtypes including other organ-specific subtypes of extranodal NHL. The 5- and 10-year survival proportions for PCNSL are 29.3% and 21.6%, respectively. The diagnosis and management of PCNSL differs from that of other primary brain cancers and NHL in other parts of the body.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.379","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"379-385","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Primary central nervous system lymphoma"],"prefix":"10.1182","volume":"2016","author":[{"given":"Tracy T.","family":"Batchelor","sequence":"first","affiliation":[{"name":"Departments of Neurology and Radiation Oncology, Division of Hematology\/Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703370812200_B1","volume-title":"Lymphoma and Leukemia of the Nervous System","author":"Batchelor","year":"2013"},{"key":"2019111703370812200_B2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro-oncol"},{"key":"2019111703370812200_B3","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"17","key":"2019111703370812200_B4","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111703370812200_B5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111703370812200_B6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/annonc\/mdt385","article-title":"Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma","volume":"25","author":"Ponzoni","year":"2014","journal-title":"Ann Oncol"},{"issue":"22","key":"2019111703370812200_B7","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111703370812200_B8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","article-title":"Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium","volume":"16","author":"Chan","year":"2011","journal-title":"Oncologist"},{"issue":"36","key":"2019111703370812200_B9","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703370812200_B10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703370812200_B11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cncr.21583","article-title":"Initial response to glucocorticoids","volume":"106","author":"Mathew","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"2019111703370812200_B12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejso.2004.10.002","article-title":"Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases","volume":"31","author":"Bellinzona","year":"2005","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"2019111703370812200_B13","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/neuonc\/nos159","article-title":"Surgery for primary CNS lymphoma? Challenging a paradigm","volume":"14","author":"Weller","year":"2012","journal-title":"Neuro-oncol"},{"issue":"1","key":"2019111703370812200_B14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","article-title":"Non-Hodgkin\u2019s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315","volume":"23","author":"Nelson","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"2019111703370812200_B15","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703370812200_B16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","article-title":"Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas","volume":"90","author":"Ferreri","year":"2004","journal-title":"Br J Cancer"},{"issue":"4","key":"2019111703370812200_B17","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","article-title":"High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?","volume":"16","author":"Glantz","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9700","key":"2019111703370812200_B18","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"2019111703370812200_B19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/annonc\/mdl464","article-title":"Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines","volume":"18","author":"Correa","year":"2007","journal-title":"Ann Oncol"},{"issue":"31","key":"2019111703370812200_B20","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111703370812200_B21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.0b013e318297eeba","article-title":"Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma","volume":"81","author":"Doolittle","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"2019111703370812200_B22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ana.21824","article-title":"Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma","volume":"67","author":"Juergens","year":"2010","journal-title":"Ann Neurol"},{"issue":"6","key":"2019111703370812200_B23","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07","volume":"21","author":"Batchelor","year":"2003","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111703370812200_B24","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111703370812200_B25","first-page":"103","article-title":"Addition of thiotepa and rituximab to antimetabolites significantly improves outome in primary CNS lymphoma: first randomization of the IELSG32 trial","volume":"33","author":"Ferreri","year":"2015","journal-title":"Hematol Oncol"},{"issue":"24","key":"2019111703370812200_B26","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962","volume":"21","author":"Poortmans","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703370812200_B27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1016077907952","article-title":"Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?","volume":"58","author":"Khan","year":"2002","journal-title":"J Neurooncol"},{"issue":"1","key":"2019111703370812200_B28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11060-011-0649-7","article-title":"Prophylactic intrathecal chemotherapy in primary CNS lymphoma","volume":"106","author":"Sierra del Rio","year":"2012","journal-title":"J Neurooncol"},{"issue":"10","key":"2019111703370812200_B29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"Batchelor","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"2019111703370812200_B30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1212\/WNL.0000000000000593","article-title":"High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma","volume":"83","author":"Holdhoff","year":"2014","journal-title":"Neurology"},{"issue":"11","key":"2019111703370812200_B31","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"key":"2019111703370812200_B32","author":"Illerhaus","year":"2012"},{"issue":"6","key":"2019111703370812200_B33","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9","article-title":"A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy","volume":"89","author":"Mead","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"2019111703370812200_B34","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol"},{"issue":"2","key":"2019111703370812200_B35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1215\/15228517-2008-067","article-title":"High-dose methotrexate for elderly patients with primary CNS lymphoma","volume":"11","author":"Zhu","year":"2009","journal-title":"Neuro-oncol"},{"issue":"7","key":"2019111703370812200_B36","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","article-title":"First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis","volume":"26","author":"Kasenda","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111703370812200_B37","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/annonc\/mdq712","article-title":"Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly","volume":"22","author":"Fritsch","year":"2011","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111703370812200_B38","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network","volume":"18","author":"Langner-Lemercier","year":"2016","journal-title":"Neuro-oncol"},{"key":"2019111703370812200_B39","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.84.14_supplement.P3.147","article-title":"Relapse patterns in primary CNS diffuse large B-cell lymphoma","author":"Wang","year":"2015"},{"issue":"17","key":"2019111703370812200_B40","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","article-title":"Treatment of relapsed central nervous system lymphoma with high-dose methotrexate","volume":"10","author":"Plotkin","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2019111703370812200_B41","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","article-title":"Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle Osseuse-Th\u00e9rapie Cellulaire","volume":"26","author":"Soussain","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703370812200_B42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbmt.2010.11.011","article-title":"Primary CNS lymphoma--radiation-free salvage therapy by second autologous stem cell transplantation","volume":"17","author":"Kasenda","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019111703370812200_B43","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2005.01.161","article-title":"Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma","volume":"23","author":"Nguyen","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111703370812200_B44","first-page":"174","article-title":"Phase I\/II study of TEDDI-R with Ibrutinib in untreated and relapsed\/refractory primary CNS lymphoma [abstract]","volume":"33","author":"Dunleavey","year":"2015","journal-title":"Hematol Oncol"},{"issue":"15","key":"2019111703370812200_B45","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2015.64.9897","article-title":"Phase II Trial of Temsirolimus for Relapsed\/Refractory Primary CNS Lymphoma","volume":"34","author":"Korfel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111703370812200_B46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","author":"Houillier","year":"2015","journal-title":"Neurology"},{"key":"2019111703370812200_B47","first-page":"175","article-title":"Lenalidomide is highly active in recurrent CNS lymphomas: phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide as maintenance monotherapy","volume":"33","author":"Rubenstein","year":"2015","journal-title":"Hematol Oncol"},{"issue":"3","key":"2019111703370812200_B48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1212\/01.WNL.0000106941.51340.A2","article-title":"Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study","volume":"62","author":"Lai","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"2019111703370812200_B49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ana.21214","article-title":"Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies","volume":"62","author":"Monje","year":"2007","journal-title":"Ann Neurol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/379\/1249603\/hem088356.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/379\/1249603\/hem088356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T23:47:19Z","timestamp":1718927239000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/379\/20973\/Primary-central-nervous-system-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.379","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}